Simvastatin Articles
Stock Commentary - New York
29 March 2004
AstraZeneca's Crestor hold 6.1% of US NRx statins market
22 March 2004
Positive new data for AstraZeneca's Crestor
15 March 2004
J&J buys Merck & Co's Eurpean consumer medicines JVC
8 March 2004
Rx-OTC switches: global momentum grows
16 February 2004
Second FDA drug imports "blitz" finds 80% come from Canada
9 February 2004
Stock Commentary - New York
2 February 2004
Merck & Co 4th-qtr in line with estimates; net income down 23%
2 February 2004
Intron slump, charges lead to S-P loss
2 February 2004
Indian firms urge govt over life-saving drugs
5 January 2004
World retail drug sales grew 8% in year to November 2003, says IMS
30 November 2003
Merck & Co strikes $272M development deal with Actelion
15 December 2003
Australia/US trade deal stumbles over PBS
15 December 2003
UPDATE: Merck & Co strikes $272M Actelion deal
15 December 2003
Merck & Co strikes $272M Actelion deal
8 December 2003
Merck & Co in new $160M drug alliance
8 December 2003
UK considering OTC low-dose statins
24 November 2003
Crestor sales could be crimped by WellPoint
20 October 2003
Spain's new Rx reference price scheme "will strangle R&D and cut profits up to 25%"
22 September 2003
Bristol-Myers Squibb warned by FDA over Pravachol ads
18 August 2003
US uninsured "pay 72% more for Rx than govt"
21 July 2003
Tokyo pharma stocks - week to July 14
21 July 2003
Tokyo pharma stocks - week to July 7
14 July 2003
Stock Commentary - Tokyo
14 July 2003
Stock Commentary - New York
30 June 2003
Zocor has life-saving benefits in diabetics
23 June 2003
New Zocor 40mg label cites HPS data
28 April 2003
Update - AstraZeneca 's Crestor: ACC studies
7 April 2003
Bently says Merck & Co is suing its Spanish unit
10 February 2003
New launches planned at Bayvit
1 July 2002
Tokyo pharma stocks - week to June 17
24 June 2002
Stock Commentary - New York
17 June 2002
Merck warns of Zocor, Cordarone interaction
17 June 2002
Banyu says Proscar still on file in Japan
3 June 2002
New Zetia data back up product rationale
13 May 2002
World drug sales up 12% in year to Feb
22 April 2002
France's top-selling Rx drugs in 2001
15 April 2002
Zetia boosts response to statin therapy
25 March 2002
Merck gets Zocor patent extension
11 March 2002
Tokyo pharma stocks - week to January 28
4 February 2002
Five key products continue to drive Merck & Co sales in 2001
28 January 2002
Genaissance completes enrollment in STRENGTH II study.
21 January 2002
Tokyo pharma stocks - week to January 14.
21 January 2002
Merck, S-P file in USA for cholesterol drug
7 January 2002
Merck & Co and S-P expand cholesterol partnership
7 January 2002
Merck & Co and S-P expand cholesterol partnership
20 December 2001
Merck & Co issues profit warning
12 December 2001
Merck points to robust pipeline despite near-term profits warning
12 December 2001
Tokyo pharma stocks - week to December 10
11 December 2001
World drug sales up 11% in year to Sept
3 December 2001
12% reduced death risk with Merck & Co's Zocor: study
15 November 2001
Merck & Co turnover up 13% but Vioxx sales are slowing down
19 October 2001
Genaissance begins second STRENGTH study
19 October 2001
Merck & Co sales up 13% for 3rd qtr
18 October 2001
World retail drug sales grew 11% in 12 months to July 2001, reports IMS
28 September 2001
Pharma DTC web sites failing to address consumer needs, says study
14 September 2001
Analysts comment on Crestor safety data
14 September 2001
Crestor "as safe as other statins"
13 September 2001
French price cuts for GSK, Lilly, Merck drugs
16 August 2001
Merck plans ezetimibe filing before 2002
15 August 2001
Five drugs push Merck & Co sales up 25%
23 July 2001
US state seniors Rx costs compared globally
18 July 2001
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
